TheraRadar
Data updated: May 26, 2026

COLISTIMETHATE SODIUM

Infectious Disease Approved 1999-02-26

COLISTIMETHATE SODIUM is indicated for the treatment of Bacterial Infections.

Source: FDA Label • NEXUS
6
Indications
--
Phase 3 Trials
27
Years on Market

Details

Status
Discontinued
First Approved
1999-02-26
Routes
INJECTION
Dosage Forms
INJECTABLE

COLISTIMETHATE SODIUM Approval History

2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
25 FDA actions from 1999 to 2023
Jun 2023 SUPPL
Label · Labeling
Sep 2021 SUPPL
Label · Labeling
Mar 2021 SUPPL
Label · Labeling

What COLISTIMETHATE SODIUM Treats

1 indications

COLISTIMETHATE SODIUM is approved for 1 conditions since its original approval in 1999. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Bacterial Infections
Source: FDA Label

COLISTIMETHATE SODIUM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to COLISTIMETHATE SODIUM

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

COLY-MYCIN M
COLISTIMETHATE SODIUM
1 shared
PH HEALTH
Shared indications:
Bacterial Infections
📋

Clinical Trial Registry

6 trials
Trial Sponsor ID Phase Status Title
NCT06488794 ColiPed FThabet Ph 2, Ph 3 not yet recruiting Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia
NCT06893835 MDRS Multidrug resistance Ph 4 active not recruiting Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline
NCT03397914 103 Ph 4 completed Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections
NCT01863719 10-0082 HHSN272201500007I Ph 1 terminated Aerosolized and Intravenous Colistin in Healthy Adults
NCT02966457 DEHAM HEM-3_1 Ph 4 completed A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)
NCT01449838 114490 Ph 1 completed Phase I Study of Colistin Methanesulfonate Sodium
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

COLISTIMETHATE SODIUM FDA Label Details

Indications & Usage

COLISTIMETHATE SODIUM is indicated for the treatment of Bacterial Infections.

Looking for the branded version?

COLY-MYCIN M

Full clinical data, patents, trials, and competitive landscape for colistimethate sodium.

See COLY-MYCIN M

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.